Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease.

Here are 10 companies to watch in 2025, each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

👉🏻 Ask us for the full list of 148 Seattle Bio/Pharma Companies & Receive it FREE in your inbox!

Avalyn Pharma

Highlight: $100 M Series D funding and advancing two inhaled antifibrotic programs in 2025.

Avalyn Pharma is redefining pulmonary care with next-generation inhaled antifibrotic therapies designed to treat chronic lung diseases such as idiopathic pulmonary fibrosis (IPF). Backed by an oversubscribed $100 million Series D completed in July 2025, the company is progressing two key programs: AP01 (inhaled pirfenidone), which continues to demonstrate long-term safety and tolerability in extension studies, and AP02 (inhaled nintedanib), which has completed Phase 1 with favorable lung exposure and safety data ahead of Phase 2 initiation. These milestones underscore Avalyn’s position as one of Seattle’s leading late-stage respiratory biotech innovators.

Arzeda

Highlight: ~$6.3 M and ~$7.8 M NSF funding to scale AI-driven enzyme and cell-free biomanufacturing technologies.

Arzeda is pioneering the design of novel enzymes and proteins using its proprietary Intelligent Protein Design Technology™ platform. In 2025, the company secured two major National Science Foundation (NSF) awards, a $6.3 million grant to lead a consortium advancing AI-driven cell-free biomanufacturing, followed by an additional $7.8 million grant to develop electricity-powered enzyme cascades for sustainable chemical production. Combining synthetic biology, machine learning, and sustainability, Arzeda is positioning Seattle as a global hub for computational protein design.

Callio Therapeutics

Highlight: US $187 million Series A funding and a cutting-edge multi-payload ADC platform.

Callio Therapeutics, co-headquartered in Seattle and Singapore, launched in early 2025 with a $187 million Series A round led by Frazier Life Sciences to advance its innovative multi-payload antibody-drug conjugate (ADC) technology. The company licensed its ADC platform and pipeline from Hummingbird Bioscience and is now progressing toward clinical proof-of-concept for a HER2-targeted dual-payload program. With substantial financing and a bold scientific strategy, Callio has quickly established itself as one of Seattle’s most promising oncology startups.

Umoja Biopharma

Highlight: $100 M oversubscribed Series C funding to advance the in vivo CAR-T platform.

Umoja Biopharma is pioneering a new era of in vivo cell therapies, aiming to reprogram immune cells directly inside the patient’s body. In January 2025, the company announced an oversubscribed $100 million Series C round, supporting the clinical advancement of its in vivo CAR-T and T-cell receptor (TCR) platforms. By eliminating the need for complex ex vivo manufacturing, Umoja streamlines cell therapy delivery and broadens patient access, cementing its role as one of Seattle’s most transformative immunotherapy innovators.

Lumen Bioscience

Highlight: Raised US $30 million in an equity round and advancing a unique biologics-delivery platform.

Lumen Bioscience is redefining biologic drug manufacturing by using the edible cyanobacterium spirulina as a high-yield production and oral-delivery system for therapeutic proteins. Its patented platform enables cost-effective, large-scale manufacture of biologics, previously limited to injectable formats, and is now being applied to indications such as metabolic and gastrointestinal diseases. With the recent $30 M funding round and a production platform that blends manufacturing innovation with therapeutic ambition, Lumen stands out as a bold Seattle biotech to watch.

Sound Pharmaceuticals

Highlight: Phase 3 clinical trial underway for SPI-1005 in Ménière’s disease.

Sound Pharmaceuticals continues to lead in the underserved field of auditory medicine. In March 2025, the company initiated an open-label Phase 3 clinical trial evaluating SPI-1005 (ebselen) for the treatment of Ménière’s disease, a chronic inner-ear disorder that causes hearing loss and vertigo. The study aims to assess long-term safety and therapeutic benefit in patients with active disease. As one of the few late-stage companies in otology drug development, Sound Pharma represents Seattle’s growing strength in precision therapeutics for sensory disorders.

HDT Bio

Highlight: Phase 1 trial launched for RNA vaccine against Crimean-Congo hemorrhagic fever.

HDT Bio continues to push the boundaries of RNA-based immunotherapies with its self-amplifying RNA (saRNA) vaccine platform. In January 2025, the company began a Phase 1 open-label, dose-escalation trial evaluating HDT-321, a vaccine candidate targeting Crimean-Congo hemorrhagic fever, a severe tick-borne viral disease with limited prevention options. This study expands HDT’s growing saRNA vaccine portfolio, underscoring the company’s leadership in developing scalable RNA solutions for infectious diseases and oncology.

Truveta

Highlight: $320 M funding to expand AI-powered health and genetic data platform.

Truveta is redefining how real-world and genetic data accelerate healthcare research. In January 2025, the company secured $320 million in funding to enhance its AI-driven data analytics and genomic integration platform, designed to connect de-identified clinical and genetic records across major healthcare systems. By unifying massive datasets under a privacy-preserving framework, Truveta is enabling faster drug discovery, improved clinical insights, and more equitable healthcare outcomes, positioning it among Seattle’s most data-centric biotech innovators.

InduPro

Highlight: Advancing proximity-based therapeutics with proprietary ProXiMATE™ and MInt platforms.

InduPro is pioneering a new dimension in drug discovery by targeting the spatial relationships of proteins on cell surfaces. Its proprietary ProXiMATE™ engine maps the cell surface proteome to reveal novel protein interactions, enabling the development of proximity-based therapeutics that address unmet needs in oncology and immunology. Complementing this, InduPro’s MInt platform uses AI and machine learning to analyze protein microenvironments and identify new therapeutic targets and co-target pairs, particularly tumor-associated proximity antigens (TAPAs).

Outpace Bio

Highlight: Phase 1 clinical trial for OPB-101 in platinum-resistant ovarian cancer.

Outpace Bio is engineering the next generation of cell therapies through synthetic biology and protein-design innovation. The company’s lead candidate, OPB-101, entered a Phase 1 clinical trial in June 2025 for platinum-resistant and recurrent ovarian cancer, marking its transition from platform development to clinical validation. Outpace’s modular approach enables precise control over cell function, durability, and tumor-specific targeting, addressing key limitations of traditional cell therapies. By merging computational protein engineering with therapeutic design, Outpace is positioning itself as a front-runner in the evolution of engineered cell medicines.

Closing Thoughts

Seattle’s biopharma ecosystem is firing on all cylinders, from Avalyn’s $100 M Series D and Umoja’s in vivo CAR-T therapies to Lumen’s spirulina-based biologics and InduPro’s AI-powered proximity therapeutics. Together, these ten companies reflect a city defined by scientific diversity, clinical ambition, and investor confidence. Whether it’s RNA vaccines, synthetic biology, or intelligent protein design, Seattle’s innovators are not just following trends; they’re setting new standards for the industry.

But in a region where innovation moves fast, it takes more than headlines to spot the real breakthroughs. BiopharmIQ helps you cut through the noise, tracking funding rounds, clinical progress, and technology shifts so you can identify the true signals shaping Seattle’s life sciences landscape. 🔗 Explore BiopharmIQ’s Exciting Free Lists

How can you get the most out of these lists?

Start by creating a free BiopharmIQ account or requesting a free trial to explore our platform in detail.

You’re also welcome to book a demo with our team, who can walk you through the platform and show you how to tailor insights to your specific business development needs.

Article History:

11/12/25 MD, DG

Not legal, investing, or tax advice.